[en] During 50 years of intensive research, we have learnt about the pathophysiology of multiple myeloma (MM) and improved the management of this disease [...].
Disciplines :
Hematology
Author, co-author :
Caers, Jo ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
The Road to a Cure: Emerging Treatments for Multiple Myeloma.
Publication date :
2020
Journal title :
Cancers
eISSN :
2072-6694
Publisher :
Multidisciplinary Digital Publishing Institute (MDPI), Switzerland
Kumar, S.K.; Rajkumar, V.; Kyle, R.A.; van Duin, M.; Sonneveld, P.; Mateos, M.; Gay, F.; Anderson, C.K. Multiple myeloma. Nat. Rev. Dis. Prim. 2017, 3, 17046. [CrossRef]
Furukawa, Y.; Kikuchi, J. Molecular basis of clonal evolution in multiple myeloma. Int. J. Hematol. 2020, 111, 496–511. [CrossRef] [PubMed]
Jasielec, J.; Kubicki, T.; Raje, N.; Vij, R.; Reece, D.; Berdeja, J.; Derman, B.A.; A Rosenbaum, C.; Richardson, P.G.; Gurbuxani, S.; et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood 2020. [CrossRef] [PubMed]
D’Agostino, M.; Bertamini, L.; Oliva, S.; Boccadoro, M.; Gay, F. Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies. Cancers 2019, 11, 2015. [CrossRef]
Tamura, H.; Ishibashi, M.; Sunakawa-Kii, M.; Inokuchi, K. Immunotherapy for Multiple Myeloma. Cancers 2019, 11, 2009. [CrossRef] [PubMed]
Caers, J.; De Larrea, C.F.; Leleu, X.; Heusschen, R.; Zojer, N.; Decaux, O.; Kastritis, E.; Minnema, M.; Jurczyszyn, A.; Beguin, Y.; et al. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. Oncologist 2016, 21, 333–342. [CrossRef] [PubMed]
Caers, J.; Garderet, L.; Kortüm, K.M.; O’Dwyer, M.E.; van de Donk, N.W.C.J.; Binder, M.; Dold, S.M.; Gay, F.; Corre, J.; Beguin, Y.; et al. An European Myeloma Network recommendation on tools for diagnosis and monitoring of Multiple Myeloma: What to use and when. Haematolgica 2018. [CrossRef] [PubMed]
Durie, B.G.M.; Hoering, A.; Abidi, M.H.; Rajkumar, S.V.; Epstein, J.; Kahanic, S.P.; Thakuri, M.; Reu, F.; Reynolds, C.M.; Sexton, R.; et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. Lancet 2017, 389, 519–527. [CrossRef]
Facon, T.; Kumar, S.; Plesner, T.; Orlowski, R.Z.; Moreau, P.; Bahlis, N.; Basu, S.; Nahi, H.; Hulin, C.; Quach, H.; et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N. Engl. J. Med. 2019, 380, 2104–2115. [CrossRef] [PubMed]
Papadimitriou, K.; Tsakirakis, N.; Malandrakis, P.; Vitsos, P.; Metousis, A.; Orologas-Stavrou, N.; Ntanasis-Stathopoulos, I.; Kanellias, N.; Eleutherakis-Papaiakovou, E.; Pothos, P.; et al. Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers 2020, 12, 3245. [CrossRef] [PubMed]
